ALTEOGEN Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Soon-Jae Park

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	19.7%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Feb 18

Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

Dec 27

AMMINISTRATORE DELEGATO

Soon-Jae Park

no data

Mandato

Dr. Soon-Jae Park, Ph D., serves as the Chief Executive Officer of ALTEOGEN Inc. He has several years of experience in R&D of biomedicine. He served as the Executive Officer at BINEX Co., Ltd.He started w...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Soon-Jae Park	Chief Executive Officer	no data	Nessun dato	19.67% ₩ 3.1t
Hang Yeon Kim	CFO & Executive VP	2.8yrs	Nessun dato	Nessun dato
Sang Woo Kang	Senior Vice President of Management Support Group	2.8yrs	Nessun dato	Nessun dato
Tae-Yon Chun	Executive VP & Corporate Alliance Officer (CAO)	4.8yrs	Nessun dato	Nessun dato
Kyuwan Kim	Senior VP & Head of New Drug Development	no data	Nessun dato	Nessun dato
Vivek B Shenoy	Chief Business Development Officer	2.8yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

Gestione esperta: Il team dirigenziale di A196170 è considerato esperto (durata media dell'incarico 2.8 anni).

ALTEOGEN Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Recent updates

New major risk - Share price stability

Alteogen Inc. Receives Ministry of Food and Drug Safety (Mfds) Approval for Tergase®

ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

Full year 2023 earnings released: ₩65.00 loss per share (vs ₩159 loss in FY 2022)

ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Now 21% overvalued after recent price rise

Consensus revenue estimates decrease by 13%

Consensus revenue estimates increase by 41%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: ₩148 loss per share (vs ₩122 loss in 3Q 2022)

Price target increased by 23% to ₩83,333

Consensus revenue estimates fall by 24%

Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to ₩62,667

Consensus forecasts updated

Price target decreased to ₩70,000

Consensus forecasts updated

Price target decreased to ₩79,000

Price target decreased to ₩106,000

Forecast breakeven date pushed back to 2022

Price target increased to ₩142,000

ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability

Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients

New 90-day low: ₩132,700

Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

New 90-day low: ₩143,700

ALTEOGEN Inc. announced that it has received KRW 74.999925 billion in funding from SG Core Co., Ltd.

Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

Analysts update estimates

ALTEOGEN Inc. announced that it expects to receive KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation

New 90-day low: ₩155,700

New 90-day high - ₩209,000

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media